Compositions and methods for the diagnosis and treatment of tumor

Patent metadata

Field	Value
Publication number	US-9994643-B2
Application number	US-201615341261-A
Country	US
Kind code	B2
Filing date	Nov 2, 2016
Priority date	Nov 30, 2009
Publication date	Jun 12, 2018
Grant date	Jun 12, 2018

Abstract

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

First claim

What is claimed is:

1. An isolated antibody that binds the polypeptide of SEQ ID NO:2 comprising:
(a) a CDR-L1 sequence of SEQ ID NO:23;
(b) a CDR-L2 sequence of SEQ ID NO:36;
(c) a CDR-L3 sequence of SEQ ID NO:41;
(d) a CDR-H1 sequence of SEQ ID NO:43;
(e) a CDR-H2 sequence of SEQ ID NO:48; and
(f) a CDR-H3 sequence of SEQ ID NO:65.

2. The isolated antibody of claim 1 further comprising a VH acceptor human consensus framework sequence of any one of SEQ ID NOS:66-75.

3. The isolated antibody of claim 1 further comprising a VL acceptor human consensus framework sequence of any one of SEQ ID NOS:76-79.

4. The isolated antibody of claim 1 further comprising a VH acceptor human consensus framework sequence of any one of SEQ ID NOS:66-75 and a VL acceptor human consensus framework sequence of any one of SEQ ID NOS:76-79.

5. The antibody of claim 1 which is an antibody fragment.

6. The antibody of claim 1 which is a chimeric or a humanized antibody.

7. The antibody of claim 1 which is conjugated to a growth inhibitory agent.

8. The antibody of claim 1 which is conjugated to a cytotoxic agent.

9. The antibody of claim 8 , wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

10. The antibody of claim 9 , wherein the cytotoxic agent is a toxin.

11. The antibody of claim 10 , wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

12. The antibody of claim 10 , wherein the toxin is an auristatin.

13. The antibody of claim 12 , wherein the toxin is monomethyl auristatin E (MMAE).

14. The antibody of claim 12 , wherein the toxin is monomethyl auristatin F (MMAF).

15. The antibody of claim 1 , which is conjugated to maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-monomethyl auristatin E (MC-val-cit-PAB-MMAE).

16. The antibody of claim 1 which is produced in bacteria.

17. The antibody of claim 1 which is produced in CHO cells.

18. The antibody of claim 8 which induces death of a cell to which it binds.

19. The antibody of claim 18 , wherein said cell is an ovarian cancer cell.

20. The antibody of claim 18 , wherein said cell is a lung cancer cell.

21. The antibody of claim 1 which is detectably labeled.

22. An isolated antibody that binds the polypeptide of SEQ ID NO:2 comprising the VL sequence of SEQ ID NO:8 and a VH sequence of SEQ ID NO:17.

23. The antibody of claim 22 which is conjugated to MC-val-cit-PAB-MMAE.

24. A therapeutic formulation comprising the antibody of claim 15 and a carrier, excipient or stabilizer.

25. The therapeutic formulation of claim 24 , wherein the antibody is at a concentration of about 5-200 mg/ml.

Assignees

• Genentech Inc

Inventors

• Dennis Mark
• Rubinfeld Bonnee
• Polakis Paul

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• G01N33/57545

  of the ovaries · CPC title

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/5752

  of the lungs · CPC title